BRAF and neoplasm: Subjects with the BRAF V600E mutation had significantly more frequent occult metastases (p = 0.008), classic PTC variant (p < 0.001), significantly smaller tumor sizes (p = 0.021), and a higher rate of CPSF2 3+ expression (p = 0.049).